GlassScriptPhysician profile
Farah Al-Saffar
NPI 1972846285
$23,784.47
in general payments reported to CMS, 2019-2025
15 companies · $3,021 in 2025
The $3,021 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $73.43 · 2021: $153 · 2022: $45.67 · 2023: $7,619 · 2024: $12K · 2025: $3,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $1,714 · Travel and Lodging: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,835.00 |
| Food and Beverage | $1,714.24 |
| Travel and Lodging | $597.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,884.81 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $9,046.88 | 2023-2025 | Jardiance |
| Medtronic Vascular, INC. | $1,024.00 | 2019-2020 | |
| Abbott Laboratories | $539.61 | 2019-2023 | Mitraclip |
| Abiomed | $341.15 | 2021-2025 | Impella |
| Cvrx, INC. | $305.81 | 2024-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $206.27 | 2021-2025 | |
| Livanova USA, INC. | $142.46 | 2023 | Protekduo |
| Actelion Pharmaceuticals US, INC. | $128.12 | 2023 | Opsumit, Uptravi |
| Ancora Heart, INC. | $56.01 | 2025 | Accucinch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.27 | 2023-2024 | Lifevest |
| Nuwellis, INC. | $19.66 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $18.88 | 2024 | |
| Pfizer INC. | $15.87 | 2022 | |
| Amarin Pharma, INC. | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Al-Saffar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.